Santen Pharmaceutical Co., Ltd. (FRA:SZD)

Market Cap	2.87B -4.2%
Revenue (ttm)	1.56B -4.6%
Net Income	166.21M +11.3%
EPS	0.50 +18.7%
Shares Out	n/a
PE Ratio	17.24
Forward PE	n/a
Dividend	0.21 (2.41%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Average Volume	3
Open	8.75
Previous Close	8.70
Day's Range	8.75 - 8.75
52-Week Range	8.05 - 10.20
Beta	n/a
RSI	37.48
Earnings Date	May 12, 2026

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan...

• Industry: Pharmaceutical Preparations
• Founded: 1890
• Employees: 3,849
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SZD

Financial Performance

In fiscal year 2025, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.

Financial numbers in JPY